Comparing of Nymox Pharmaceutical Corporation (NYMX) and Aridis Pharmaceuticals Inc. (NASDAQ:ARDS)

Nymox Pharmaceutical Corporation (NASDAQ:NYMX) and Aridis Pharmaceuticals Inc. (NASDAQ:ARDS), are influenced by contrast since they are both players in the Biotechnology. These factors are particularly influence the profitability, analyst recommendations, institutional ownership, risk, dividends, earnings and valuation of the two firms.

Valuation & Earnings

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Nymox Pharmaceutical Corporation 2 0.00 39.97M -0.17 0.00
Aridis Pharmaceuticals Inc. 5 0.00 5.59M -2.88 0.00

We can see in table 1 the earnings per share (EPS), gross revenue and valuation of Nymox Pharmaceutical Corporation and Aridis Pharmaceuticals Inc.

Profitability

Table 2 provides us the return on equity, return on assets and net margins of both companies.

Net Margins Return on Equity Return on Assets
Nymox Pharmaceutical Corporation 2,109,346,139.64% -175.8% -144.9%
Aridis Pharmaceuticals Inc. 103,903,345.72% 0% -85.4%

Liquidity

Nymox Pharmaceutical Corporation’s Current Ratio and Quick Ratio are 8 and 8 respectively. The Current Ratio and Quick Ratio of its competitor Aridis Pharmaceuticals Inc. are 4.5 and 4.5 respectively. Nymox Pharmaceutical Corporation therefore has a better chance of paying off short and long-term obligations compared to Aridis Pharmaceuticals Inc.

Insider & Institutional Ownership

Nymox Pharmaceutical Corporation and Aridis Pharmaceuticals Inc. has shares held by institutional investors as follows: 6% and 0.7%. Nymox Pharmaceutical Corporation’s share held by insiders are 5.4%. Insiders Comparatively, held 45.04% of Aridis Pharmaceuticals Inc. shares.

Performance

Here are the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD)
Nymox Pharmaceutical Corporation 0.58% 21.99% -4.97% -17.31% -45.57% 31.3%
Aridis Pharmaceuticals Inc. -8.23% -18.69% -16.75% -0.23% 0% -21.55%

For the past year Nymox Pharmaceutical Corporation had bullish trend while Aridis Pharmaceuticals Inc. had bearish trend.

Summary

Nymox Pharmaceutical Corporation beats Aridis Pharmaceuticals Inc. on 6 of the 9 factors.

Nymox Pharmaceutical Corporation, a biopharmaceutical company, engages in the research and development of drugs for the aging population. It markets NicAlert and TobacAlert test strips that use urine or saliva to detect use of tobacco products. The company also offers AlzheimAlert, a proprietary urine assay that aids physicians in the diagnosis of AlzheimerÂ’s disease. Its lead drug candidate is Fexapotide Triflutate (NX-1207), which is in Phase III clinical trials for the treatment of enlarged prostate or benign prostatic hyperplasia, as well as is in Phase II clinical trial for low grade localized prostate cancer. The company markets its products in Canada, the United States, Europe, and internationally. Nymox Pharmaceutical Corporation was founded in 1989 and is headquartered in Nassau, The Bahamas.

Aridis Pharmaceuticals Inc., a late-stage biopharmaceutical company, focuses on the discovery and development of targeted immunotherapy using fully human monoclonal antibodies (mAb) to treat life-threatening infections. Its lead product candidate is AR-301, a fully human mAb of immunoglobulin 1 (IgG1) that is in Phase III pivotal trials for the treatment of lung infections resulting from S. aureus alphatoxin. The company is also developing AR-105, a fully human IgG1 mAb, which is in Phase II trials to target gram-negative bacteria P. aeruginosa; AR-101, a human IgM mAb that is in Phase IIa trials for the treatment of hospital-acquired pneumonia (HAP)and ventilator-associated pneumonia (VAP) caused by P. aeruginosa serotype O11; AR-401 to treat infections caused by A. baumannii; AR-201, an anti- respiratory syncytial virus F-protein mAb; and AR-501, an anti-infective therapy to manage chronic lung infections in cystic fibrosis patients and acute pneumonia in HAP and VAP patients. Aridis Pharmaceuticals Inc. was founded in 2003 and is headquartered in San Jose, California.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.